# Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)

> **NCT01512901** · PHASE2,PHASE3 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.**

## Conditions studied

- Macular Edema Following Branch Retinal Vein Occlusion

## Interventions

- **DRUG:** Betamethasone Microsphere (DE-102） Low Dose
- **DRUG:** Betamethasone Microsphere (DE-102） High Dose
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT01512901
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01512901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01512901, "Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01512901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*